Authors: Pastukh I.1, Goncharova N.1, Nedzvetskaya O.1, Chubenko I.2
1 Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine
2 Medical Center “Oftalmika”, Kharkiv, Ukraine
Abstract
The aim of the investigation was to increase the effectiveness of the treatment of glaucoma optical neuropathy (GON) by using the metabolic drug Cocarnit (World Medicine pharmaceutical company) in the complex treatment of patients with primary open-angle glaucoma (POAG). The study included 30 patients (41 eyes) with II–III (a) stages of POAG, while compensating for intraocular pressure (IOP) with instillations of brimonidine drops. All patients underwent standard ophthalmological, clinical and additional instrumental studies. To stimulation maintain visual function, all patients underwent courses of therapy, including different groups of drugs. As a metabolic therapy, the drug Cocarnit was used, which was prescribed intramuscularly in 3.0 ml daily, for a course of 9 injections.
After the courses of treatment, the patient’s visual acuity increased, the peripheral boundaries of the visual field expanded, and the sizes of central and paracentral scotomas decreased, raise photosensivity retina. The observed effect persisted for 3 to 4 months.
Keywords: primary open-angle glaucoma (POAG), retinal ganglion cells, intraocular pressure (IOP), perimetry, optical coherence tomography, Cocarnit.